Project Grant R01AI198368
Award Date 8/3/26
Completion Date 7/31/31
Dollars Obligated $449K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $853,847 to Massachusetts General Hospital on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds characterization of virologic and immunologic features of RSV immunoprophylaxis and escape. The recipient will sequence the genomes of approximately 3,000 biobanked and prospectively collected respiratory syncytial virus...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin System $615,446 on April 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into arterivirus entry, transmission, and persistence mechanisms. The research examines how arteriviruses—an understudied family of RNA viruses related to coronaviruses—enter cells, evade immunity, and cause disease. The work focuses on the neonatal Fc receptor (FcRn) and its...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $191,376 on August 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to map escape mutations in respiratory syncytial virus fusion protein and monitor for antibody-resistant viral strains. The recipient will develop a deep mutational scanning platform to comprehensively measure the effects of all possible mutations on cell entry and neutralization by clinically...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin - Madison $414,861 under Project Grant R21AI195857 on September 1, 2026, through the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the evolutionary pathways by which influenza virus variants acquire antiviral resistance. The investigator will use engineered viral libraries carrying random nucleotide barcodes on the PA segment of the influenza genome to...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin System $475,681 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate tools for interrogating the functions, interactions, and cellular localizations of HIV-1 alternatively spliced transcript variants. The research comprises two aims. Aim 1 develops sensitive, multiplexed assays (HYPR-MS) to elucidate the protein interactomes of up to 20...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $130,923 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop data-science approaches for evaluating and forecasting respiratory syncytial virus transmission. The research addresses knowledge gaps in how host factors—age, contact patterns, and within-host viral load kinetics—shape individual infectiousness and RSV disease transmission. The work comprises three...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin–Madison $1,650,321 on August 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct longitudinal research on early life epithelial development and asthma risk through the Childhood Allergy and the Neonatal Environment (CANOE) study. The award funds analysis of serial nasal cell samples collected from study participants beginning at birth through age 5 years to...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin–Madison $146,920 on November 30, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into the molecular mechanisms of bacterial multidrug efflux transporters and antimicrobial resistance. The funded research combines deep mutational scanning with in vivo and in vitro validation to characterize how the NorA efflux transporter exports structurally and...
- The National Institute of Allergy and Infectious Diseases awarded Sciogen LLC $314,363 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel therapeutics targeting respiratory syncytial virus (RSV) infection through G-receptor binding inhibition. The Phase I Small Business Innovation Research award funds evaluation of a new class of RSV inhibitors identified through high-throughput screening. Work includes assessment of biological...
- The National Institute of Allergy and Infectious Diseases awarded University of Kansas Medical Center Research Institute, Inc. $193,750 on July 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct exploratory research on the role of cell-surface glycoRNAs in respiratory syncytial virus infection. The research will define the sequences and secondary structures of glycoRNAs that scaffold nucleolin, an RNA-binding protein and critical RSV entry receptor, on...